Search results
Advanced applications. Impactful discoveries. The NovaSeq 6000 System offers deep, broad coverage through advanced applications for a comprehensive view of the genome. Unlock a full spectrum of genetic variation and biological function with high-throughput sequencing. See all NovaSeq 6000 applications.
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of ...
Illumina solutions in next-generation sequencing (NGS) and microarray technologies deliver fast, accurate information that can guide choices and transform lives at multiple touchpoints along the reproductive and genetic health journey. The Verifi Prenatal Test was developed by, and its performance characteristics were determined by Verinata ...
Overcoming the challenges in PMS2 high-homology regions for improved detection of pathogenic variants associated with Lynch syndrome. Read publication. Illumina sequencing and array technologies drive advances in life science research, translational and consumer genomics, and molecular diagnostics.
Delivering Value to Investors. A global leader in DNA sequencing and array-based technologies, Illumina is fueling advancements in life sciences, oncology, reproductive health, genetic disease, agriculture, microbiology, and other emerging segments. We are dedicated to improving human health by unlocking the power of the genome.
Jun 26, 2024 · Overcoming the challenges in PMS2 high-homology regions for improved detection of pathogenic variants associated with Lynch syndrome. Illumina sequencing and array technologies drive advances in life science research, translational and consumer genomics, and molecular diagnostics.
Sep 29, 2022 · Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced multiple breakthrough sequencing innovations at its inaugural Illumina Genomics Forum: The launch of NovaSeq™ 6000 Dx as the first FDA-registered and CE-marked in vitro diagnostic (IVD) high-throughput sequencer, delivering the highest standards of compliance and driving actionable ...
